Betrixaban for first-line venous thromboembolism prevention in acute medically ill patients with risk factors for venous thromboembolism

References

• Anderson FA Jr., Zayaruzny M, Heit JA, et al. Estimated annual numbers of US acute-care hospital patients at risk for venous thromboembolism. Am J Hematol. 2007;82(9):777–782.
   PubMed Web of Science ®Google Scholar
• Cohen AT, Agnelli G, Anderson FA, et al. Venous thromboembolism (VTE) in Europe. The number of VTE events and associated morbidity and mortality. Thromb Haemost. 2007;98(4):756–764.
   PubMed Web of Science ®Google Scholar
• Raskob GE, Angchaisuksiri P, Blanco AN, et al. Thrombosis: a major contributor to global disease burden. Arterioscler Thromb Vasc Biol. 2014;34(11):2363–2371.
   PubMed Web of Science ®Google Scholar
• Vaitkus PT, Leizorovicz A, Cohen AT, et al. Mortality rates and risk factors for asymptomatic deep vein thrombosis in medical patients. Thromb Haemost. 2005;93(1):76–79.
   PubMed Web of Science ®Google Scholar
• Goldhaber SZ, Visani L, De Rosa M. Acute pulmonary embolism: clinical outcomes in the International Cooperative Pulmonary Embolism Registry (ICOPER). Lancet. 1999;353(9162):1386–1389.
   PubMed Web of Science ®Google Scholar
• Heit JA, O’Fallon WM, Petterson TM, et al. Relative impact of risk factors for deep vein thrombosis and pulmonary embolism: a population-based study. Arch Intern Med. 2002;162(11):1245–1248.
   PubMedGoogle Scholar
• Kahn SR, Lim W, Dunn AS, et al. Prevention of VTE in nonsurgical patients: antithrombotic therapy and prevention of thrombosis, 9th ed: American college of chest physicians evidence-based clinical practice guidelines. Chest. 2012;141(2 Suppl):e195S–226S.
   PubMed Web of Science ®Google Scholar
• Geerts WH, Bergqvist D, Pineo GF, et al. Prevention of venous thromboembolism: American college of chest physicians evidence-based clinical practice guidelines (8th Edition). Chest. 2008;133(6 Suppl):381S–453S.
   PubMed Web of Science ®Google Scholar
• Cohen AT, Alikhan R, Arcelus JI, et al. Assessment of venous thromboembolism risk and the benefits of thromboprophylaxis in medical patients. Thromb Haemost. 2005;94(4):750–759.
   PubMed Web of Science ®Google Scholar
• Korjian S, Daaboul Y, Halaby R, et al. Extended-duration thromboprophylaxis among acute medically ill patients: an unmet need. J Cardiovasc Pharmacol Ther. 2016;21(3):227–232.
   PubMed Web of Science ®Google Scholar
• Amin AN, Varker H, Princic N, et al. Duration of venous thromboembolism risk across a continuum in medically ill hospitalized patients. J Hosp Med. 2012;7(3):231–238.
   PubMed Web of Science ®Google Scholar
• Fanikos J, Stevens LA, Labreche M, et al. Adherence to pharmacological thromboprophylaxis orders in hospitalized patients. Am J Med. 2010;123(6):536–541.
   PubMed Web of Science ®Google Scholar
• Cohen AT, Harrington R, Goldhaber SZ, et al. The design and rationale for the acute medically ill venous thromboembolism prevention with extended duration betrixaban (APEX) study. Am Heart J. 2014;167(3):335–341.
   PubMed Web of Science ®Google Scholar
• Temple R. Guidance for industry: enrichment strategies for clinical trials to support approval of human drugs and biological products. Services DoHaH, ed. MD: Silver Spring; 2012.
   Google Scholar
• Cohen AT, Harrington R, Goldhaber SZ, et al. Recognition of biomarker identified high-risk patients in the acute medically ill venous thromboembolism prevention with extended duration betrixaban study resulting in a protocol amendment. Am Heart J. 2015;169(1):186–187.
   PubMed Web of Science ®Google Scholar
• Gibson CM, Goldhaber SZ, Cohen AT, et al. When academic research organizations and clinical research organizations disagree: processes to minimize discrepancies prior to unblinding of randomized trials. Am Heart J. 2017;189:1–8.
   PubMed Web of Science ®Google Scholar
• Cohen AT, Harrington RA, Goldhaber SZ, et al. Extended thromboprophylaxis with betrixaban in acutely ill medical patients. N Engl J Med. 2016;375(6):534–544.
   PubMed Web of Science ®Google Scholar
• Gibson CM, Halaby R, Korjian S, et al. The safety and efficacy of full- versus reduced-dose betrixaban in the acute medically ill VTE (Venous Thromboembolism) prevention with extended-duration betrixaban (APEX) trial. Am Heart J. 2017;185:93–100.
   PubMed Web of Science ®Google Scholar
• Gibson CM, Nafee T, Yee MK, et al. Symptomatic event reduction with extended-duration betrixaban in acute medically ill hospitalized patients. Am Heart J. 2018;198:84–90.
   PubMed Web of Science ®Google Scholar
• Arbetter DF, Jain P, Yee MK, et al. Competing risk analysis in a large cardiovascular clinical trial: an APEX substudy. Pharm Stat. 2017;16(6):445–450.
   PubMed Web of Science ®Google Scholar
• Yee MK, Nafee T, Daaboul Y, et al. Increased benefit of betrixaban among patients with a history of venous thromboembolism: a post-hoc analysis of the APEX trial. J Thromb Thrombolysis. 2018;45(1):1–8.
   PubMed Web of Science ®Google Scholar
• Chi G, Goldhaber SZ, Hull RD, et al. Thrombus burden of deep vein thrombosis and its association with thromboprophylaxis and D-dimer measurement: insights from the APEX trial. Thromb Haemost. 2017;117(12):2389–2395.
   PubMed Web of Science ®Google Scholar
• Gibson CM, Chi G, Halaby R, et al. Extended-duration betrixaban reduces the risk of stroke versus standard-dose enoxaparin among hospitalized medically ill patients: an APEX trial substudy (Acute medically ill venous thromboembolism prevention with extended duration betrixaban). Circulation. 2016.
   Web of Science ®Google Scholar
• Gibson CM, Korjian S, Chi G, et al. Comparison of fatal or irreversible events with extended-duration betrixaban versus standard dose enoxaparin in acutely ill medical patients: an APEX trial substudy. J Am Heart Assoc. 2017;6(7).
   Web of Science ®Google Scholar
• Chi G, Yee MK, Amin AN, et al. Extended-duration betrixaban reduces the risk of rehospitalization associated with venous thromboembolism among acutely ill hospitalized medical patients: findings from the APEX trial (Acute medically ill venous thromboembolism prevention with extended duration betrixaban trial). Circulation. 2018;137(1):91–94.
   PubMed Web of Science ®Google Scholar
• Chan NC, Bhagirath V, Eikelboom JW. Profile of betrixaban and its potential in the prevention and treatment of venous thromboembolism. Vasc Health Risk Manag. 2015;11:343–351.
   PubMed Web of Science ®Google Scholar
• Samama MM, Meddahi S, Samama CM. Pharmacology and laboratory testing of the oral Xa inhibitors. Clin Lab Med. 2014;34(3):503–517.
   PubMed Web of Science ®Google Scholar
• Hull RD, Schellong SM, Tapson VF, et al. Extended-duration venous thromboembolism prophylaxis in acutely ill medical patients with recently reduced mobility: a randomized trial. Ann Intern Med. 2010;153(1):8–18.
   PubMed Web of Science ®Google Scholar
• Goldhaber SZ, Leizorovicz A, Kakkar AK, et al. Apixaban versus enoxaparin for thromboprophylaxis in medically ill patients. N Engl J Med. 2011;365(23):2167–2177.
   PubMed Web of Science ®Google Scholar
• Cohen AT, Spiro TE, Buller HR, et al. Rivaroxaban for thromboprophylaxis in acutely ill medical patients. N Engl J Med. 2013;368(6):513–523.
   PubMed Web of Science ®Google Scholar
• Zhang P, Huang W, Wang L, et al. Discovery of betrixaban (PRT054021), N-(5-chloropyridin-2-yl)-2-(4-(N,N-dimethylcarbamimidoyl)benzamido)-5-methoxybenz amide, a highly potent, selective, and orally efficacious factor Xa inhibitor. Bioorg Med Chem Lett. 2009;19(8):2179–2185.
   PubMed Web of Science ®Google Scholar
• Jia ZJ, Scarborough RM, Zhang P, et al. Design, synthesis and discovery of 1-(2-(6-Chloro-3-methylsulfonyl)-naphthyl)-1H-pyrazole-5-carboxylamides as highly potent factor Xa inhibitors. Chem Pharm Bull (Tokyo). 2009;57(9):1004–1007.
   PubMed Web of Science ®Google Scholar